Aptamer Group

ICYMI - Technology Networks covered our exciting news of a refreshed Scientific Advisory Board, welcoming global experts across siRNA delivery, radioligands and drug development. https://lnkd.in/gtcAjG4C

We're #hiring a new Business Development Manager in York, England. Apply today or share this post with your network. What’s in it for you? - Competitive salary & benefits (think private healthcare, holiday purchase schemes, and more!) - Flexibility to work from home. - A chance to make a real impact in a thriving, innovative industry.

Announcing a new contract with a rare disease biopharmaceutical company for Optimer development to provide critical reagents for bioanalysis of a developing therapy. Read more: https://lnkd.in/gmzuyhpS

Looking to kickstart your career in science? We’re hiring a Laboratory Scientist Degree Apprentice at Aptamer Group—an opportunity to gain hands-on lab experience, grow your skills, and work alongside a team driving innovation in life sciences. If you’re curious, motivated, and ready to make a real impact, we’d love to hear from you! Find out more and apply here: https://lnkd.in/ejQ_V5p7

Our aptamer discovery process has cell-screens built in meaning aptamers are validated for live or fixed cell and tissue applications right from the start.   Tailored to your targets, specific to your assay needs, and unlimited by performance. Derisk your research with Optimer. https://bit.ly/4iaPulW

Delivering RNA therapies to the site of action is not easy for many cell types or tissues. Optimer delivery vehicles can help overcome the major issues of: 🎯 selective targeting to specific cell types  🧬  internalization of the RNA therapeutic payload to the target cell  💊  ensuring the therapy is functional once in the cell Watch our on-demand webinar to understand how we develop Optimers as therapeutic vectors that overcome each of these challenges and how this can help advance your precision therapies. https://lnkd.in/gDvfJphR

Join our CEO, @ArronTolley, and CSO, David Bunka, in an investor webinar tomorrow, 12 December 2024 at 6.00 pm (GMT) with Q&A to learn more about the latest announcements from Aptamer Group. Register and submit your questions here: https://lnkd.in/g2B2tCXJ #APTA

Congratulations to Aptamer Sciences Inc. on progressing their drug for liver cancer to phase 1 clinical trials. Using an aptamer-based delivery vehicle, AST-201 targets GPC3-positive advanced solid tumors with a gemcitabine chemotherapy payload for new approaches in liver cancer. https://lnkd.in/gZag69_p Aptamer Group is also developing a delivery vehicle targeting liver fibrosis - an earlier stage in the progression of liver disease, with the aim of inhibiting or reversing fibrosis so that patients may never reach later stages of the disease. This could prevent patients with liver disease progressing to cancer or requiring liver transplants. See more here: https://bit.ly/3CYCkZ9

Need better IHC reagents? 👩🔬 Want to localise new targets? Optimer offer tuned IHC reagents for direct and secondary detection. If you need animal-free reagents for high sensitivity, high specificity assays see how Optimer can help.🔬

Could precision therapies change the future of liver disease treatment? Aptamer Group’s Optimer®-siRNA conjugates are showing real promise in targeting and silencing genes in fibrotic liver cells. Download their poster to see the data for yourself: https://lnkd.in/eyCPRnbC #liverdisease #precisiontherapy